Land: USA
Språk: engelsk
Kilde: NLM (National Library of Medicine)
METOCLOPRAMIDE HYDROCHLORIDE (UNII: W1792A2RVD) (METOCLOPRAMIDE - UNII:L4YEB44I46)
Preferred Pharmaceuticals, Inc.
METOCLOPRAMIDE HYDROCHLORIDE
METOCLOPRAMIDE 10 mg
ORAL
PRESCRIPTION DRUG
The use of metoclopramide tablets, USP is recommended for adults only. Therapy should not exceed 12 weeks in duration. Metoclopramide tablets, USP are indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy. The principal effect of metoclopramide is on symptoms of postprandial and daytime heartburn with less observed effect on nocturnal symptoms. If symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. Healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of a 12-week trial using doses of 15 mg q.i.d. As there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically. Metoclopramide tablets, USP are indicated for the
Each white to off white, capsule shaped biconvex metoclopramide tablets, USP with "RF11" embossed on one side & score line on the other side contains 10 mg of metoclopramide base as metoclopramide hydrochloride, USP. Available in: Bottle of 30 - 68788-9093-3 Dispense tablets in tight, light-resistant container. Store between 20° and 25° C (68° and 77° F) [See USP Controlled Room Temperature]. You may report side effects to FDA at 1-800-FDA-1088.
Abbreviated New Drug Application
METOCLOPRAMIDE- METOCLOPRAMIDE TABLET Preferred Pharmaceuticals, Inc. ---------- MEDICATION GUIDE Metoclopramide Tablets, USP Read the Medication Guide that comes with metoclopramide tablets before you start taking it and each time you get a refill. There may be new information. If you take another product that contains metoclopramide (such as metoclopramide injection, metoclopramide orally disintegrating tablets, or metoclopramide oral syrup), you should read the Medication Guide that comes with that product. Some of the information may be different. This Medication Guide does not take the place of talking with your doctor about your medical condition or your treatment. What is the most important information I should know about metoclopramide tablets? Metoclopramide tablets can cause serious side effects, including: Tardive dyskinesia (abnormal muscle movements). These movements happen mostly in the face muscles. You can not control these movements. They may not go away even after stopping metoclopramide tablets. There is no treatment for tardive dyskinesia, but symptoms may lessen or go away over time after you stop taking metoclopramide tablets. Your chances for getting tardive dyskinesia go up: • the longer you take metoclopramide tablets and the more metoclopramide tablets you take. You should not take metoclopramide tablets for more than 12 weeks. • if you are older, especially if you are a woman • if you have diabetes It is not possible for your doctor to know if you will get tardive dyskinesia if you take metoclopramide tablets. Call your doctor right away if you get movements you can not stop or control, such as: • lip smacking, chewing, or puckering up your mouth • frowning or scowling • sticking out your tongue • blinking and moving your eyes • shaking of your arms and legs See the section "What are the possible side effects of metoclopramide tablets?" for more information about side effects. What are metoclopramide tablets? Metoclopramide tablets are a prescription medicine used: • i Les hele dokumentet
METOCLOPRAMIDE- METOCLOPRAMIDE TABLET PREFERRED PHARMACEUTICALS, INC. ---------- METOCLOPRAMIDE TABLETS, USP RX ONLY WARNING: TARDIVE DYSKINESIA TREATMENT WITH METOCLOPRAMIDE CAN CAUSE TARDIVE DYSKINESIA, A SERIOUS MOVEMENT DISORDER THAT IS OFTEN IRREVERSIBLE. THE RISK OF DEVELOPING TARDIVE DYSKINESIA INCREASES WITH DURATION OF TREATMENT AND TOTAL CUMULATIVE DOSE. METOCLOPRAMIDE THERAPY SHOULD BE DISCONTINUED IN PATIENTS WHO DEVELOP SIGNS OR SYMPTOMS OF TARDIVE DYSKINESIA. THERE IS NO KNOWN TREATMENT FOR TARDIVE DYSKINESIA. IN SOME PATIENTS, SYMPTOMS MAY LESSEN OR RESOLVE AFTER METOCLOPRAMIDE TREATMENT IS S TOPPED. TREATMENT WITH METOCLOPRAMIDE FOR LONGER THAN 12 WEEKS SHOULD BE AVOIDED IN ALL BUT RARE CASES WHERE THERAPEUTIC BENEFIT IS THOUGHT TO OUTWEIGH THE RISK OF DEVELOPING TARDIVE DYS KINES IA. SEE WARNINGS DESCRIPTION For oral administration, metoclopramide tablets, USP 10 mg are white to off white, capsule shaped, biconvex tablets with "RF11" embossed on one side and score line on the other side. Each tablet contains: 10 mg of metoclopramide base as metoclopramide hydrochloride, USP INACTIVE INGREDIENTS Microcrystalline cellulose, corn starch, pregelatinized starch, colloidal silicon dioxide and stearic acid. Metoclopramide tablets, USP 5 mg are white to off white, oval shaped, biconvex tablets with "RF10" embossed on one side and plain on the other side. Each tablet contains: 5 mg of metoclopramide base as metoclopramide hydrochloride, USP INACTIVE INGREDIENTS Microcrystalline cellulose, corn starch, pregelatinized starch, colloidal silicon dioxide and stearic acid. Metoclopramide hydrochloride is a white crystalline, odorless substance, freely soluble in water. Chemically, it is 4-amino-5-chloro-N-[2-(diethylamino) ethyl]-2-methoxy benzamide monohydrochloride monohydrate. Its molecular formula is C H CIN O •HCI•H O. Its molecular weight is 354.3. 14 22 3 2 2 CLINICAL PHARMACOLOGY Metoclopramide stimulates motility of the upper gastrointestinal tract without stimulating gastric, biliary, or pancreati Les hele dokumentet